TY  - JOUR
AU  - Kelleher, AD
AU  - Puls, RL
AU  - Bebbington, M
AU  - Boyle, D
AU  - Ffrench, R
AU  - Kent, SJ
AU  - Kippax, S
AU  - Purcell, DFJ
AU  - Thomson, S
AU  - Wand, H
AU  - Cooper, DA
AU  - Emery, S
Y2  - 2014/05/21
Y1  - 2006/01/09
SN  - 0269-9370
UR  - http://hdl.handle.net/11343/26433
AB  - An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 x 10(7) pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.
N1  - application/pdf
LA  - English
PB  - LIPPINCOTT WILLIAMS & WILKINS
KW  - Medical Virology ; Infectious Diseases
T1  - A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1
DO  - 10.1097/01.aids.0000199819.40079.e9
IS  - AIDS
VL  - 20
IS  - 2
SP  - 294-297
L1  - /bitstream/handle/11343/26433/116229_5278.pdf?sequence=1&isAllowed=n
ER  -